Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (41-50 of 266) with videos related to

Pageof 27
Sort By:
Interactive Cardiovascular and Thoracic Surgery|December 1, 2009
Parabolic resection for mitral valve repairDaniel H Drake, Charles G Drake, Dino Recchia
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2014
Immunotherapy for brain cancer: recent progress and future promiseChristopher M Jackson, Michael Lim, Charles G Drake
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to SelectCharles G Drake, Trinity J Bivalacqua, Noah M Hahn
Urology|February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future researchJulie N Graff, Charles G Drake, Tomasz M Beer
Discovery Medicine|May 28, 2016
Recent advances in immunotherapy for kidney cancerMark W Ball, Mohamad E Allaf, Charles G Drake
Nature Reviews. Clinical Oncology|May 1, 2014
Reply: Regulatory T cells-an important target for cancer immunotherapyCharles G Drake, Evan J Lipson, Julie R Brahmer
Cancer Research|April 22, 2014
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancerW Nathaniel Brennen, Charles G Drake, John T Isaacs
Cancer Immunology Research|December 7, 2014
PD-1 blockade in renal cell carcinoma: to equilibrium and beyondLauren C Harshman, Charles G Drake, Toni K Choueiri
Current Opinion in Immunology|January 13, 2012
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L Topalian, Charles G Drake, Drew M Pardoll
Cancer Cell|April 11, 2015
Immune checkpoint blockade: a common denominator approach to cancer therapySuzanne L Topalian, Charles G Drake, Drew M Pardoll
Pageof 27

Showing results (41-50 of 266) with videos related to

Sort By:
Pageof 27
Interactive Cardiovascular and Thoracic Surgery|December 1, 2009
Parabolic resection for mitral valve repairDaniel H Drake, Charles G Drake, Dino Recchia
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2014
Immunotherapy for brain cancer: recent progress and future promiseChristopher M Jackson, Michael Lim, Charles G Drake
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to SelectCharles G Drake, Trinity J Bivalacqua, Noah M Hahn
Urology|February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future researchJulie N Graff, Charles G Drake, Tomasz M Beer
Discovery Medicine|May 28, 2016
Recent advances in immunotherapy for kidney cancerMark W Ball, Mohamad E Allaf, Charles G Drake
Nature Reviews. Clinical Oncology|May 1, 2014
Reply: Regulatory T cells-an important target for cancer immunotherapyCharles G Drake, Evan J Lipson, Julie R Brahmer
Cancer Research|April 22, 2014
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancerW Nathaniel Brennen, Charles G Drake, John T Isaacs
Cancer Immunology Research|December 7, 2014
PD-1 blockade in renal cell carcinoma: to equilibrium and beyondLauren C Harshman, Charles G Drake, Toni K Choueiri
Current Opinion in Immunology|January 13, 2012
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L Topalian, Charles G Drake, Drew M Pardoll
Cancer Cell|April 11, 2015
Immune checkpoint blockade: a common denominator approach to cancer therapySuzanne L Topalian, Charles G Drake, Drew M Pardoll
Pageof 27